Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Revicki

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Journal of Psychiatry & Neuroscience : JPN|July 1, 1997
Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophreniaD A Revicki
Schizophrenia Research|April 6, 1999
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophreniaD A Revicki
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidenceD A Revicki
The Journal of Family Practice|October 1, 1989
Health-related quality of life in the evaluation of medical therapy for chronic illnessD A Revicki
Medical Care|July 1, 1985
Dependability of medical encounter diagnostic informationD A Revicki
Medical Care|May 1, 1992
Relationship between health utility and psychometric health status measuresD A Revicki
Expert Opinion on Pharmacotherapy|March 16, 2001
The new atypical antipsychotics: a review of pharmacoeconomic studiesD A Revicki
Medical Care|July 1, 1984
The dependability of medical encounter diagnostic informationD A Revicki
The Journal of Clinical Psychiatry|February 26, 1999
Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studiesD A Revicki
Gut|April 15, 2004
Patient assessment of treatment satisfaction: methods and practical issuesD A Revicki
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Journal of Psychiatry & Neuroscience : JPN|July 1, 1997
Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophreniaD A Revicki
Schizophrenia Research|April 6, 1999
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophreniaD A Revicki
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidenceD A Revicki
The Journal of Family Practice|October 1, 1989
Health-related quality of life in the evaluation of medical therapy for chronic illnessD A Revicki
Medical Care|July 1, 1985
Dependability of medical encounter diagnostic informationD A Revicki
Medical Care|May 1, 1992
Relationship between health utility and psychometric health status measuresD A Revicki
Expert Opinion on Pharmacotherapy|March 16, 2001
The new atypical antipsychotics: a review of pharmacoeconomic studiesD A Revicki
Medical Care|July 1, 1984
The dependability of medical encounter diagnostic informationD A Revicki
The Journal of Clinical Psychiatry|February 26, 1999
Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studiesD A Revicki
Gut|April 15, 2004
Patient assessment of treatment satisfaction: methods and practical issuesD A Revicki
Pageof 12